Indivior stock after-hours at EUR 31.50: plus 0.00 percent versus Lang & Schwarz prior close
Indivior stock traded at EUR 31.50 after-hours on October 2, 2026, showing no change from its Lang & Schwarz prior close. The company announced a contingent special cash dividend of USD 8.13 per share, payable upon the closing of its planned merger with Supernus Pharmaceuticals, Inc., expected around November 2, 2026. This dividend is conditional on the merger's completion, with a record date of October 30, 2026, and payment anticipated around November 6, 2026.
Indivior declares USD 8.13 dividend. Indivior stock gains 1.27 percent
Indivior has declared a conditional special cash dividend of USD 8.13 per share, dependent on the completion of its merger with Supernus Pharmaceuticals. The company also reported a 14.00 percent increase in Q2 2026 revenue to USD 343.00 million, with SUBLOCADE revenue up 21.00 percent. Indivior's stock saw a 1.27 percent gain, trading at EUR 31.90.
Indivior stock: company declares conditional USD 8.13 special dividend
Indivior Pharmaceuticals has declared a conditional special cash dividend of USD 8.13 per share. This payment is contingent upon the successful completion of its proposed merger with Supernus Pharmaceuticals. If the merger, expected around November 2, 2026, closes as planned, the dividend will be paid on or about November 6, 2026, to shareholders of record as of October 30, 2026.
Indivior stock last trades at USD 36.88 on September 28, 2026
Indivior shares closed at USD 36.88 on Nasdaq on September 28, 2026, marking a 2.96% increase from the previous day's close. The company had previously declared a conditional special cash dividend of USD 8.13 per share, contingent on the successful merger with Supernus Pharmaceuticals, expected to close around November 2, 2026. If the merger is completed, the dividend is anticipated to be paid around November 6, 2026.
Indivior stock at USD 35.82 on September 25, 2026
Indivior stock was last quoted at USD 35.82 on September 25, 2026. The company has declared a conditional special cash dividend of USD 8.13 per share, payable upon the closing of its proposed merger with Supernus Pharmaceuticals, Inc., which is expected around November 2, 2026. The stock was down 0.50 percent from its previous close on Nasdaq under the ticker INDV.
INDV IMPORTANT DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Indivior PLC Investors with Losses in Excess of $100K to Secure Counsel Before Important October 1 Deadline in Securities Class Action - INDV
The Rosen Law Firm is encouraging investors of Indivior PLC (NASDAQ: INDV) who incurred losses exceeding $100,000 to join a securities class action lawsuit. The deadline to serve as lead plaintiff is October 1, 2024. The lawsuit alleges that Indivior made false and misleading statements about its business, operations, and financial prospects, particularly concerning the impact of legislation on its products and its revenue guidance for Fiscal Year 2024.
Indivior stock carries a USD 8.13 special dividend
Indivior stock announced a USD 8.13 special dividend, contingent on the completion of its merger with Supernus Pharmaceuticals, which is expected to close on November 2, 2026. The record date for the dividend is October 30, 2026, with payment anticipated on November 6, 2026. The company also reported strong Q2 2026 financial results, with revenue up 14% year-over-year, and analysts maintain a "Moderate Buy" rating with a target price significantly above its current trading value.
Indivior stock heads into the open after a 0.14 percent fall
Indivior stock closed at USD 35.86 on September 24, 2026, marking a 0.14 percent decline with a trading volume of 50,261 shares. A rights-related announcement was made today, indicating that Addex Therapeutics has regained full global rights to certain GABAB positive allosteric modulator assets from Indivior UK Limited, following Indivior's rationalization of R&D and a planned merger with Supernus Pharmaceuticals. This announcement is expected to influence the stock's performance in the upcoming session.
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
Addex Therapeutics has reacquired full global rights to its GABAB positive allosteric modulator (PAM) assets from Indivior UK Limited. This decision by Indivior to rationalize R&D activities and a planned merger with Supernus Pharmaceuticals, Inc. led to the return of these rights. Addex now has the flexibility to independently advance its GABAB PAM portfolio, including the returned candidate for substance use disorders and its proprietary candidate for chronic cough, allowing exploration of various strategic options.
Indivior stock heads into the open after a 0.77 percent drop
Indivior stock closed down 0.77 percent at USD 35.91 on Nasdaq on September 23, 2026, underperforming the Nasdaq Composite which fell 1.13 percent. The company's stock is currently 15.9 percent below its 52-week high but USD 13.46 above its 52-week low. Indivior has also declared an USD 8.13 special dividend tied to a planned merger with Supernus Pharmaceuticals, with a record date of October 30, 2026, and a payment date of November 6, 2026.
Indivior Pharmaceuticals stock reports USD 8.13 special dividend
Indivior Pharmaceuticals has declared a special dividend of USD 8.13 per share, contingent on its planned merger with Supernus Pharmaceuticals. The company also reported strong Q2 2026 results, with revenue up 13.6% to USD 343 million and adjusted EPS rising 125.5% to USD 1.15, leading to an increased full-year revenue guidance. The dividend is payable to shareholders of record on October 30, 2026, with payment scheduled for November 6, 2026, making the merger's completion a critical value driver for existing shareholders.
Indivior stock heads into the open after closing at USD 34.88
Indivior stock closed at USD 34.88 on the Nasdaq on September 20, 2026, with a reported market capitalization of USD 4.4 billion. This closing price represented approximately 77.2% of the average analyst target of USD 45.17. The article provides financial data for Indivior PLC (ISIN GB00BYZ0C031).
Indivior stock stands at USD 34.88 below analyst targets
Indivior stock traded at USD 34.88 on September 20, 2026, which is USD 10.29 below the average analyst target of USD 45.17, implying a 29.5% difference. The company's market capitalization was USD 4.4 billion on the same date. This discrepancy highlights the gap between the market's valuation and analysts' expectations for Indivior.
Indivior stock heads into the open after a flat Nasdaq close
Indivior stock closed at USD 34.88 on Nasdaq on September 18, 2026, remaining flat against the previous session and broadly aligning with the healthcare sector's modest movements. Analysts currently hold a "Moderate Buy" consensus with an average 12-month price target of USD 45.17, indicating potential undervaluation compared to its market price and a model-derived fair value of USD 40.63. Investors are focusing on these analyst views and valuation metrics as the new trading day begins, with no specific company events scheduled.
Indivior (INDV) Receives a Rating Update from a Top Analyst
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on Indivior (INDV). The company reported a quarterly revenue of $343 million and a net profit of $122 million for the quarter ending June 30. Corporate insider sentiment is positive, with an increase in insider buying over the past quarter.
Indivior declares $8.13 contingent special dividend
Indivior Pharmaceuticals (NASDAQ:INDV) has declared a contingent special cash dividend of $8.13 per share. This dividend is dependent on the successful completion of its merger with Supernus Pharmaceuticals. Shareholders of record as of October 30, 2026, are expected to receive payment around November 6, 2026, provided the merger closes as planned.
Form 8K Indivior PLC For: 17 September By Investing.com
This article reports that Indivior PLC filed a Form 8K on September 17, 2026. The brief announcement provides no further details on the content of the filing but mentions the company's stock symbol INDV, which was up 3.14% at the time of publication. The article is primarily a placeholder for the filing information, surrounded by general financial news and market data.
Form 8K Indivior PLC For: 15 September By Investing.com
This article from Investing.com reports that Indivior PLC filed a Form 8K for September 15. The content is primarily a placeholder or brief announcement, with the majority of the page filled with financial market data, popular news links, and various navigational elements common to a financial news platform.
Form 8K Indivior PLC For: 15 September By Investing.com
This article from Investing.com announces the filing of Form 8K by Indivior PLC for September 15. The brief piece reiterates the company name, the form filed, and the date, accompanied by its stock symbol INDV and a positive price change. It appears to be a very concise news alert about a corporate filing.
Indivior Pharmaceuticals to end supply agreement with Reckitt Benckiser in January
Indivior Pharmaceuticals will terminate its supply agreement with Reckitt Benckiser Healthcare (UK) Limited on January 15, 2027, an accelerated termination for the manufacture of SUBOXONE and SUBUTEX tablets. Indivior has secured a new supplier, and the financial implications of the termination and new agreement are not expected to be material to the company. This development follows recent news of Indivior's strong Q2 2026 results and a planned merger with Supernus Pharmaceuticals.
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?
Indivior Pharmaceuticals Inc. (INDV) shares have dropped 5.3% since its last earnings report, underperforming the S&P 500. The company, however, beat Q2 2026 earnings estimates, reporting adjusted earnings of $1.15 per share and revenues of $343 million, primarily driven by strong U.S. Sublocade performance. Indivior also raised its full-year 2026 financial guidance, projecting net revenues between $1.295-$1.365 billion and adjusted EBITDA of $700-$740 million, reflecting strong commercial execution and market demand.
Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Indivior Pharmaceuticals Inc. (INDV) has experienced a 12.9% decline in stock price over the past four weeks, but indicators suggest a potential trend reversal. The stock's Relative Strength Index (RSI) is in oversold territory at 28.53, and Wall Street analysts have increased their earnings estimates for the current year. Additionally, INDV holds a Zacks Rank #2 (Buy), further indicating a possible turnaround.
Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Indivior Pharmaceuticals Inc. (INDV) has experienced a 12.9% decline over the past four weeks, but indicators suggest a potential trend reversal. Its Relative Strength Index (RSI) of 28.53 indicates the stock is oversold, while Wall Street analysts have raised earnings estimates, leading to a Zacks Rank #2 (Buy). These factors combined point to a possible rebound in the near term for INDV.
Indivior stock holds near $36 after a buyback run
Indivior stock has maintained a price near $36.11, boasting high profitability margins and significant revenue and EPS growth. Despite recent insider sales, the company's strong financial health, modest debt, and core products like SUBLOCADE and SUBOXONE Film suggest continued performance tied to operational execution. The stock remains above its 200-day moving average and has seen a 53.31% gain over the last 12 months.
Indivior stock holds firm after record quarter and Supernus merger plan
Indivior Plc's stock is trading at an elevated level following a record quarter and the announcement of a planned merger with Supernus. The company reported record revenue and profit, driven by its opioid use disorder treatments, with a P/E ratio of 13 and a market capitalization of $4.6 billion. The Supernus merger aims to diversify Indivior's neuroscience-related treatments and sustain future growth, with investors evaluating the integration risks against the strong financial performance.
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan
Indivior Pharmaceuticals (INDV) is considered significantly undervalued, trading at a discount to analyst targets and intrinsic value, despite a recent 9% monthly dip. The company's "Action Agenda," aiming to reduce non-essential spending by at least US$150 million annually and cap 2026 operating expenses at US$450 million, is expected to boost adjusted EBITDA and free cash flow. This strategy, coupled with anticipated strong SUBLOCADE uptake, supports a fair value estimate of $53.00, suggesting a 30.4% undervaluation.
Reasons Why Investors Should Consider Betting on Indivior Stock
Indivior Pharmaceuticals (INDV) is positioned as a strong investment due to the commercial success of its opioid use disorder treatment, Sublocade, which has seen significant adoption and market share growth. The company also demonstrates disciplined capital allocation by focusing on high-value opportunities and implementing cost-optimization programs. Indivior currently holds a Zacks Rank #1 (Strong Buy), with positive earnings per share estimates for 2026 and 2027.
Indivior stock holds firm as Supernus merger and higher 2026 EBITDA outlook reshape the story
Indivior stock is currently being evaluated by investors in light of a proposed merger with Supernus Pharmaceuticals and an upgraded 2026 adjusted EBITDA outlook ranging from $700 million to $740 million. The company's key product, Sublocade, continues to drive significant revenue growth and patient adoption, contributing to increased profitability. While valuation metrics present a mixed picture of premium sales multiples and discounted fair value estimates, the potential Supernus merger is expected to further broaden Indivior's pipeline and substantially increase pro forma revenues and EBITDA.
Is Indivior Stock a Buy After Higher 2026 Guidance?
Indivior (INDV) has shown strong first-quarter 2026 results and raised its full-year guidance, primarily driven by the success of its opioid use disorder treatment, Sublocade. The company is also focusing on profitability, cost control, and shareholder returns through share repurchases. Investors should monitor Sublocade's continued growth and margin durability to assess the stock's future performance.
Indivior stock gains new growth option with proposed Supernus merger and raised 2026 EBITDA outlook
Indivior stock is gaining attention due to a proposed merger with Supernus Pharmaceuticals, which aims to expand its central nervous system pipeline and diversify its revenue base. The company also raised its 2026 adjusted EBITDA outlook to $700-$740 million, signaling confidence in earnings and cost efficiencies. While analysts see potential upside, legal settlements related to opioid litigation and competitive risks for its key product, Sublocade, remain significant considerations for investors.
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
Indivior has agreed to merge with Supernus Pharmaceuticals in an all-stock deal, aiming to transform Indivior from an opioid use disorder-focused company into a broader central nervous system (CNS) firm with 11 marketed medicines. The merger is expected to provide scale, cost savings, and expanded research capabilities, targeting $125 million in annual synergies and projected revenues of $2.2 billion for the combined entity. While Indivior shareholders will hold a majority stake, the deal is contingent on closing conditions, regulatory approvals, and current litigation risks, with benefits subject to execution post-merger.
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks?
Indivior Pharmaceuticals (INDV) is experiencing accelerated demand for Sublocade, leading to higher revenues and increased earnings guidance for 2026. While the company's cost reductions are boosting profitability, investors face concentration risk due to Sublocade generating 70% of revenues, pipeline setbacks, and ongoing legal exposure. The valuation presents a mixed picture, balancing strong growth with a premium sales multiple, and a potential merger with Supernus Pharmaceuticals could offer diversification.
Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal
Indivior stock is trading around $39 following the announcement of its merger with Supernus Pharmaceuticals, targeting a combined revenue of $2.2 billion. The merger aims to create a larger specialty pharmaceutical platform focused on central nervous system and addiction-treatment products, with potential workforce streamlining. Despite minor daily fluctuations, Indivior has shown positive year-to-date performance and its current stock price is well above its 52-week low.
Indivior stock edges higher as options activity and analyst targets point to further upside
Indivior stock is trading in the high-$30s, with recent options activity and analyst targets suggesting further upside potential. The stock closed at $39.43 on August 18, 2026, and analysts have an average target of $45.17, implying a 14.5% gain. This positive outlook is supported by recent bullish options flow and a consensus of six buy ratings and one hold rating from analysts.
Indivior Pharmaceuticals, Inc. (INDV) Options Chain
This article provides the options chain for Indivior Pharmaceuticals, Inc. (INDV), listing both call and put options with their respective strike prices, last trade dates, prices, and other relevant data. It includes current stock performance and related pharmaceutical tickers.
Indivior Plc (INDV) News, Articles, Events & Latest Updates
Indivior Plc (INDV) has been actively discussed in news concerning its proposed merger with Supernus Pharmaceuticals, Inc. The merger aims to create a CNS-focused biopharmaceutical leader with potential revenues of $2.2 billion. Various investor rights law firms are investigating the adequacy of the price and process of this proposed transaction for Indivior shareholders.
Is Indivior Pharmaceuticals Inc. (INDV) a Solid Growth Stock? 3 Reasons to Think "Yes"
Indivior Pharmaceuticals Inc. (INDV) is identified as a strong growth stock due to its favorable Zacks Growth Style Score and top Zacks Rank. The article highlights three key factors: strong projected earnings growth of 46.4%, robust year-over-year cash flow growth of 36%, and promising upward revisions in earnings estimates. These indicators suggest INDV is a potential outperformer for growth investors.
Indivior PLC (INDV) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Indivior PLC (INDV), highlighting its current earnings forecast score, average price target, and analyst ratings. Based on 5 analysts, the stock has a "Buy" trend with a target price of $49.000, suggesting a 27.37% upside. The report also details expected revenue and EPS for upcoming quarters.
Hennion & Walsh Asset Management Inc. Invests $14.78 Million in Indivior PLC $INDV
Hennion & Walsh Asset Management Inc. has acquired a new stake in Indivior PLC (NASDAQ:INDV) worth approximately $14.78 million, representing 0.30% of the company. Institutional investors collectively own 60.33% of Indivior, which currently holds a "Moderate Buy" consensus rating with an average price target of $45.17. However, the company faces uncertainty due to a law firm's investigation into its proposed Supernus acquisition, raising concerns about potential share dilution.
Assenagon Asset Management S.A. Buys Shares of 1,540,928 Indivior PLC $INDV
Assenagon Asset Management S.A. has acquired 1,540,928 shares of Indivior PLC (NASDAQ:INDV), representing a 1.26% stake worth approximately $63.2 million. Institutional investors now collectively own 60.33% of the company. Indivior recently reported strong quarterly earnings of $5.75 per share, surpassing full-year analyst expectations, while the stock trades near its 50-day moving average and analysts maintain a "Moderate Buy" rating.
Indivior PLC (INDV) Stock News Today
This page provides news and analysis for Indivior PLC (INDV) stock. It includes current stock price, market capitalization, P/E ratio, and states that more news will be available soon. The platform, TradingKey, offers general information and does not provide financial advice.
Earnings call transcript: Supernus and Indivior post Q2 2026 beat on merger news
Supernus Pharmaceuticals and Indivior Pharmaceuticals announced a Q2 2026 earnings beat and their planned all-stock merger. The combined entity will focus on central nervous system drugs, aiming for $2.2 billion in annual revenue and $125 million in annual cost savings. The merger, expected to close in Q4 2026, will create a CNS leader with a diversified portfolio and enhanced financial flexibility.
HC Wainwright Predicts Indivior's Q3 Earnings (NASDAQ:INDV)
HC Wainwright has increased its Q3 2026 EPS estimates for Indivior (NASDAQ:INDV) to $0.93 from $0.78, with forecasts rising through FY2030. Despite a recent price target cut by Barclays, analyst sentiment remains a "Moderate Buy" with an average target of $45.17. Indivior's shares opened up 6.1% at $38.73, and institutional investors hold a significant portion of the stock, while recent insider transactions show both purchases and sales.
Indivior Q2 Earnings Call Highlights
Indivior and Supernus Pharmaceuticals announced an all-stock merger of equals, creating a CNS-focused biopharmaceutical company with an estimated $2.2 billion in pro forma trailing-12-month net revenue. The combined entity will retain the Supernus name and be led by Supernus CEO Jack Khattar. The merger is expected to generate $125 million in annual cost synergies and aims to leverage a diversified portfolio, with Indivior's SUBLOCADE being the largest product contributor.
Indivior Pharmaceuticals, Inc. (INDV) Stock Analysis: Analyst Consensus Points to 36% Upside Potential
Indivior Pharmaceuticals, Inc. (INDV) is positioned as a key player in opioid dependence treatment, with strong analyst consensus pointing to a 36% upside potential. The company's focus on buprenorphine-based treatments, robust revenue growth of 19.20%, and a product pipeline including SUBLOCADE and SUBOXONE contribute to its attractive outlook. Despite short-term overbought signals, its solid financial foundation and positive market sentiment make it a compelling long-term investment in the healthcare sector.
Indivior Pharmaceuticals, Inc. Quarterly Earnings Report
Indivior Pharmaceuticals, Inc. (INDV) has released its Q2 2026 earnings report, detailing an increase in net revenue driven by strong U.S. sales of SUBLOCADE. The company also announced a proposed all-stock merger with Supernus Pharmaceuticals, Inc., which includes a conditional $1 billion special cash dividend to Indivior shareholders. This report also outlines ongoing litigation, including dental allegations related to SUBOXONE Film and civil opioid lawsuits, alongside a share repurchase program.
$1.8bn merger unites Supernus and Indivior in CNS therapeutics play
Supernus Pharmaceuticals and Indivior Pharmaceutical are merging in an all-stock transaction valued at $1.8 billion, aiming to create a stronger entity in the CNS therapeutics space. The combined company, to be named Supernus, Inc., will leverage commercial and pipeline synergies across neurological and psychiatric disorders, including Parkinson's disease and addiction treatments. The merger is expected to generate $125 million in annual cost synergies by 2027 and achieve positive adjusted EBITDA in its first full year.
indivior plc. Positive Earnings Pre-Announcements
Indivior plc. (INDV.L, INDV) has pre-announced positive earnings, revising its fiscal year 2026 revenue guidance upwards from an estimated range of $1.215 - $1.285 Billion to $1.295 - $1.365 Billion. This announcement is part of a broader calendar of earnings pre-announcements available through RTTNews. The article also includes a "News for indivior plc." section, listing several recent positive financial and strategic updates for the company.
indivior plc. Positive Earnings Pre-Announcements
Indivior plc. has pre-announced positive earnings, with estimated revenue for FY26 now ranging from $1.295 - $1.365 Billion, an increase from the previous range of $1.215 - $1.285 Billion. This update was reported on August 3, 2026, by RTTNews.
Supernus, Indivior merge to beef up brain drug portfolio
Brain drug developers Supernus and Indivior have announced a merger aimed at combining their portfolios of neurological drugs. The new entity, to be called Supernus, will have a combined revenue of $2 billion (2025 figures) and aims to achieve annual cost reductions of $125 million. This strategic move is expected to create a diversified portfolio with projected sales of $2.2 billion and earnings of $888 million, with growth anticipated into the 2030s.
